117 related articles for article (PubMed ID: 1361163)
1. Cross-resistance of drug-resistant murine P388 leukemias to taxol in vivo.
Waud WR; Gilbert KS; Harrison SD; Griswold DP
Cancer Chemother Pharmacol; 1992; 31(3):255-7. PubMed ID: 1361163
[TBL] [Abstract][Full Text] [Related]
2. Lack of in vivo cross-resistance with 4'-thio-ara-C against drug-resistant murine P388 and L1210 leukemias.
Waud WR; Gilbert KS; Secrist JA
Cancer Chemother Pharmacol; 2011 Aug; 68(2):399-403. PubMed ID: 21069340
[TBL] [Abstract][Full Text] [Related]
3. Lack of in vivo crossresistance with gemcitabine against drug-resistant murine P388 leukemias.
Waud WR; Gilbert KS; Grindey GB; Worzalla JF
Cancer Chemother Pharmacol; 1996; 38(2):178-80. PubMed ID: 8616909
[TBL] [Abstract][Full Text] [Related]
4. Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia.
Waud WR; Harrison SD; Gilbert KS; Laster WR; Griswold DP
Cancer Chemother Pharmacol; 1991; 27(6):456-63. PubMed ID: 1849465
[TBL] [Abstract][Full Text] [Related]
5. [The cross resistance to cytostatics of leukemia P388 cells with induced resistance to doxorubicin].
Donenko FV; Sitdikova SM; Kabieva AO
Biull Eksp Biol Med; 1993 Sep; 116(9):309-11. PubMed ID: 8118011
[TBL] [Abstract][Full Text] [Related]
6. Antitumor drug cross-resistance in vivo in a murine P388 leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-hydroxyethanesulfonate hydrate (NSC 370,147) 370147.
Waud WR; Harrison SD; Temple CG; Griswold DP
Cancer Chemother Pharmacol; 1992; 29(3):190-4. PubMed ID: 1733551
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.
Waud WR; Plowman J; Harrison SD; Dykes DJ; Anderson WK; Griswold DP
Cancer Chemother Pharmacol; 1992; 30(4):261-6. PubMed ID: 1322803
[TBL] [Abstract][Full Text] [Related]
8. Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo.
Harrison SD; Plowman J; Dykes DJ; Waud WR; Griswold DP
Cancer Chemother Pharmacol; 1990; 25(6):425-9. PubMed ID: 2311170
[TBL] [Abstract][Full Text] [Related]
9. Cross-resistance of drug-resistant murine leukemias to deoxyspergualin (NSC 356894) in vivo.
Harrison SD; Brockman RW; Trader MW; Laster WR; Griswold DP
Invest New Drugs; 1987 Dec; 5(4):345-51. PubMed ID: 3436739
[TBL] [Abstract][Full Text] [Related]
10. Reversal of doxorubicin and cisplatin resistance in vivo in murine leukemias by the calcium antagonist RO 11-2933.
Mazzoni A; Canti G
Sel Cancer Ther; 1990; 6(4):167-76. PubMed ID: 2094936
[TBL] [Abstract][Full Text] [Related]
11. In vivo characterization of P388 leukemia resistant to mitomycin C.
Rose WC; Huftalen JB; Bradner WT; Schurig JE
In Vivo; 1987; 1(1):47-52. PubMed ID: 2979764
[TBL] [Abstract][Full Text] [Related]
12. Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells.
Knick VC; Eberwein DJ; Miller CG
J Natl Cancer Inst; 1995 Jul; 87(14):1072-7. PubMed ID: 7616599
[TBL] [Abstract][Full Text] [Related]
13. The Effectiveness of Cyclic Hydroxamic Acid CHA-5 against Drug-Resistant P388 Leukemia Strains.
Goncharova SA; Vystorop IV; Raevskaya TA; Konovalova NP
Bull Exp Biol Med; 2017 Jul; 163(3):385-388. PubMed ID: 28744633
[TBL] [Abstract][Full Text] [Related]
14. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
Fichtner I; Stein U; Hoffmann J; Winterfeld G; Pfeil D; Hentschel M
Anticancer Res; 1994; 14(5A):1995-2003. PubMed ID: 7847840
[TBL] [Abstract][Full Text] [Related]
15. Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin.
Chandrasekaran B; Dimling J; Capizzi RL
Cancer Treat Rep; 1987 Feb; 71(2):195-6. PubMed ID: 2948640
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns.
Tsuruo T; Kawabata H; Nagumo N; Iida H; Kitatani Y; Tsukagoshi S; Sakurai Y
Cancer Chemother Pharmacol; 1985; 15(1):16-9. PubMed ID: 4006044
[TBL] [Abstract][Full Text] [Related]
17. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Schmidt H; Seshadri R; Israel M
Biochem Biophys Res Commun; 1985 Sep; 131(2):912-9. PubMed ID: 2932108
[TBL] [Abstract][Full Text] [Related]
18. Potential antitumor agents. 52. Carbamate analogues of amsacrine with in vivo activity against multidrug-resistant P388 leukemia.
Rewcastle GW; Baguley BC; Atwell GJ; Denny WA
J Med Chem; 1987 Sep; 30(9):1576-81. PubMed ID: 3625706
[TBL] [Abstract][Full Text] [Related]
19. A benzophenazine derivative, N-beta-dimethylaminoethyl 9-carboxy-5-hydroxy-10-methoxy-benzo[a]phenazine-6-carboxamide, as a new antitumor agent against multidrug-resistant and sensitive tumors.
Tsuruo T; Naito M; Takamori R; Tsukahara S; Yamabe-Mitsuhashi J; Yamazaki A; Oh-hara T; Sudo Y; Nakaike S; Yamagishi T
Cancer Chemother Pharmacol; 1990; 26(2):83-7. PubMed ID: 2161296
[TBL] [Abstract][Full Text] [Related]
20. Isolation and characterization of a murine P388 leukemia line resistant to thiarabine.
Waud WR; Parker WB; Gilbert KS; Secrist JA
Nucleosides Nucleotides Nucleic Acids; 2012; 31(1):14-27. PubMed ID: 22257207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
